Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) CEO Richard A. Md Miller acquired 577,634 shares of Corvus Pharmaceuticals stock in a transaction on Monday, May 6th. The shares were bought at an average price of $1.73 per share, for a total transaction of $999,306.82. Following the purchase, the chief executive officer now owns 577,634 shares of the company’s stock, valued at $999,306.82. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Corvus Pharmaceuticals Price Performance
CRVS stock opened at $1.96 on Thursday. The firm has a market cap of $96.12 million, a price-to-earnings ratio of -3.77 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $4.19. The firm has a fifty day moving average price of $1.77 and a two-hundred day moving average price of $1.78.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). As a group, analysts expect that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current fiscal year.
Hedge Funds Weigh In On Corvus Pharmaceuticals
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Mizuho restated a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Oppenheimer lifted their price target on Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Tuesday.
Check Out Our Latest Stock Analysis on Corvus Pharmaceuticals
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Further Reading
- Five stocks we like better than Corvus Pharmaceuticals
- What is the FTSE 100 index?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What Are Dividend Champions? How to Invest in the Champions
- Generac Powers Ahead on the Electrification Mega-Trend
- ETF Screener: Uses and Step-by-Step Guide
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.